<DOC>
	<DOCNO>NCT02423915</DOCNO>
	<brief_summary>T-cells white blood cell important immune system . The T cell study ( call regulatory T-cells , Tregs ) donor relate . Before Tregs give , may change laboratory make use sugar find small amount blood cell process call fucosylation . They call fucosylated Tregs . Adding sugar Tregs laboratory design help Tregs find way faster bone marrow , may help low blood count recover faster . The goal clinical research study learn safe practical give fucosylated Tregs patient receive match related donor ( MRD ) , match unrelated donor ( MUD ) , cord blood transplant . Researchers also want learn Tregs may prevent reduce effect graft-versus host disease ( GVHD ) . GVHD result reaction transplant cord blood cell certain tissue body .</brief_summary>
	<brief_title>Fucosylated T Cells Graft Versus Host Disease ( GVHD ) Prevention</brief_title>
	<detailed_description>The day receive stem cell call minus ( - ) day . The day receive stem cell call Day 0 . The day receive stem cell call plus ( + ) day . Central Venous Catheter Placement : You first central venous catheter ( CVC ) place . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form . The chemotherapy , drug study , Tregs , MRD , MUD cord blood transplant give vein CVC . Some blood sample also draw CVC . The CVC remain body 2-5 month . Study Treatments : If find eligible take part study , assign dose level Tregs base join study . You may receive fucosylated non-fucosylated Treg cell . Two dose level fucosylated Tregs test . Up 3 participant enrol Dose Level 1 , 17 Dose Level 2 . The first group participant receive low dose level . The next group receive high dose first group , intolerable side effect see . The next 10 participant receive non-fucosylated Tregs Dose Level 2 . The last 34 patient enrol study randomly assign ( flip coin ) 1 2 study group equal chance receive either fucosylated non-fucosylated Treg cell . You receive 1 2 preparative regimen transplant . These regimen use prepare body receive transplant . Your study doctor decide regimen best . Regimen # 1 : On Day -12 , receive rituximab vein 4-6 hour , receive . This depend disease . On Day -9 , admit hospital give fluid vein hydrate . On Day -8 , receive fludarabine cyclophosphamide vein 1 hour . You also receive mesna vein 30-60 minute cyclophosphamide dose every 4 hour total 5 dos . Mesna give low risk side effect bladder cause cyclophosphamide . On Days -7 , -6 , -5 , receive fludarabine vein 1 hour . On Day -4 , receive single treatment low-dose total body irradiation part standard care stem cell transplant . You receive separate consent form describe procedure risk . On Day -1 , receive Tregs vein 30-60 minute . On Day 0 , receive stem cell transplant CVC 30 minute several hour depend donor type stem cell transplant receive . Regimen # 2 : On Day -12 , receive rituximab vein 4-6 hour , receive . This depend disease . On Day -6 , admit hospital give fluid vein hydrate . On Days -5 , -4 , -3 -2 , receive fludarabine vein 1 hour . On Day -2 , receive melphalan vein 30 min . On Day -1 , receive Tregs vein 30-60 minute . On Day 0 , receive stem cell transplant CVC 30 minute several hour depend donor type stem cell transplant receive . Supportive Drugs : You give standard drug help decrease risk side effect . You may ask study staff drug give risk . Starting Day -3 , receive sirolimus mouth day . You receive mycophenolate mofetil ( MMF ) tablet mouth 3 time day . If able take MMF tablet mouth , receive MMF vein 2 hour . If GVHD Day 100 , dose MMF gradually lower . If GVHD , MMF may stop 7 day GVHD control . If GVHD Day 180 transplant , dose sirolimus gradually lower . Your doctor discus . You receive filgrastim injection skin 1 time day , start Day 0 cord blood transplant Day 7 match relate MUD transplant , blood cell level return normal . Filgrastim design help growth white blood cell . Study Visits : As part standard care , remain hospital 4 week transplant . After release hospital , continue outpatient Houston area monitor infection transplant-related complication . On Days -10 , -1 , 0 , +1 , +3 , +7 , +14 , +21 , 1 , 2 , 3 , 6 , 12 month transplant , blood ( 3 tablespoon ) draw check immune function , response T cell , inflammatory response , GVHD marker . If possible , blood collect standard care blood draw additional needle stick need . About 1 , 3 , 6 , 12 month transplant : - You physical exam . - You check possible reaction transplant study drug , include GVHD . - Blood ( 4 teaspoon ) draw routine test , check cytomegalovirus ( CMV ) , genetic test learn body accept donor cell . - Urine collect routine test . - If doctor think need , bone marrow aspiration check status disease . To collect bone marrow aspiration/biopsy , area hip site numb anesthetic , small amount bone marrow bone withdrawn large needle . - If lymphoma Hodgkin 's Disease doctor think need , CT scan neck , chest , abdomen , pelvis check status disease . Length Study : You study 1 year . You take study early disease get bad , intolerable side effect occur , enough T cell create , unable follow study direction , doctor think best interest . This investigational study . Fucosylation Tregs FDA-approved process . It currently use research purpose . Fludarabine , melphalan , cyclophosphamide rituximab FDA approve commercially available give patient leukemia lymphoma cord blood transplant . Total body irradiation deliver use FDA-approved commercially available method . Up 47 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients high risk hematologic malignancy , include induction failure relapse . 2 . Patients must match relate matched unrelated donor source OR CB unit ( ) available primary transplant is/are match patient 4 , 5 , 6/6 HLA class I ( serological ) II ( molecular ) antigens . The cord ( ) must contain least 3 x 107 total nucleated cells/Kg recipient body weight ( prethaw ) . 3 . Age Criteria : Age &gt; /= 16 &lt; /= 80 year old . Eligibility pediatric patient determine conjunction MDACC pediatrician . 4 . Bilirubin &lt; /= 1.5 mg/dl , SGPT &lt; /= 200 IU/ml ( unless Gilbert 's syndrome ) . 5 . Calculated creatinine clearance &gt; 50 mL/min use CockcroftGault equation adult patient 18 70 year old base ideal body weight , Schwartz equation pediatric patient 6 month 17 year old . 6 . Diffusing capacity carbon monoxide ( DLCO ) &gt; /= 45 % predict correct hemoglobin . For child &lt; /= 7 year age unable perform pulmonary function test , O2 saturation &gt; /= 92 % room air . 7 . Left ventricular ejection fraction ( LEF ) &gt; /= 40 % . 8 . Zubrod performance status &lt; /= 2 Lansky &gt; /= 60 % . 9 . Twentyone day must elapse since patient 's last radiation chemotherapy administration . Hydrea , Gleevec TKI inhibitor well intrathecal therapy accept exception . 10 . A backup graft identify , case graft failure , follow source : available fraction autologous marrow ; PBPCs harvest cryopreserved ; family member donor ; third cord blood unit . 11 . Able stop CYP3A4 inhibitor ( voriconazole posaconazole ) least 7 day admission . 12 . Patient patient 's legal representative , parent ( ) guardian able sign inform consent . Age 718 able provide assent . 1 . HIV seropositivity . 2 . Uncontrolled infection , respond appropriate antimicrobial agent seven day therapy . The PI final arbiter eligibility . 3 . Positive beta HCG female childbearing potential define postmenopausal 12 month previous surgical sterilization lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Advanced hematologic malignancy</keyword>
	<keyword>Graft versus host disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Fucosylated umbilical cord blood Regulatory T cell</keyword>
	<keyword>CB</keyword>
	<keyword>Tregs</keyword>
	<keyword>T cell</keyword>
	<keyword>Cord blood transplant</keyword>
	<keyword>Total body radiation</keyword>
	<keyword>TBI</keyword>
	<keyword>Radiation therapy</keyword>
	<keyword>XRT</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Mycophenolate</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>MMF</keyword>
	<keyword>CellCept</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamune</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>